Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Ponderano – page 21

276 clinical trials in Ponderano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ponderano at a glance
276
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

276 trials in Ponderano

Open in trial search

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Lupus nephritis

Not recruiting

Study on Zetomipzomib for Patients with Active Lupus Nephritis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Kezar Life Sciences Inc.

Follicular lymphoma+2

Not recruiting

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Prostate cancer

Not recruiting

Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Study on Brigatinib and Durvalumab for Patients with Unresectable Stage III Non-Small Cell Lung Cancer with ALK Gene Change After Chemotherapy and Radiation Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Brigatinib
  • Sponsor:ETOP IBCSG Partners Foundation

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ponderano

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including colorectal cancer, lymphoma, and endometrial cancer. Studies evaluate novel therapeutic combinations and personalized treatment approaches.

  • Advanced Pancreatic Cancer Treatment
  • Lymphoma Therapy Optimization
  • Targeted Colorectal Cancer Interventions

Research emphasizes improving survival rates and treatment efficacy through immunotherapy and targeted molecular approaches.

02 Neurological Disorders

Investigations into treatments for Multiple Sclerosis and Alzheimer's Disease, with particular focus on managing associated symptoms and disease progression.

  • MS Long-term Treatment Evaluation
  • Alzheimer's-related Psychosis Management
  • Innovative Therapeutic Approaches

Studies aim to enhance quality of life and develop more effective treatment strategies.

03 Infectious Diseases

Research on treating gram-negative bacterial infections in vulnerable populations, including studies of new antibiotics and treatment protocols.

  • Neonatal Infection Treatment
  • Hospital-acquired Pneumonia
  • Complex Bacterial Infections

Focus on developing safer and more effective treatments for severe infections.

04 Addiction Medicine

Studies examining treatments for alcohol dependence, with emphasis on reducing consumption and maintaining abstinence in high-risk patients.

  • Alcohol Consumption Reduction
  • Maintenance Therapy
  • Risk Level Management

Research aims to improve treatment outcomes for alcohol-dependent individuals.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.